Recent news on Luteinizing Hormone-Releasing Hormone

AEterna Zentaris' Partner, Spectrum, Discloses Detailed Phase 2 ...  -  May 23, 2007
CNW Telbec (Communiqués de presse),About Ozarelix and Partnerships Ozarelix is a fourth generation luteinizing hormone-releasing hormone (LHRH) antagonist administered as a depot formulation

Market Report -- In Play (AEZS)  -  May 23, 2007
MSN Money...detailed Phase 2 results for AEZS' fourth-generation luteinizing hormone-releasing hormone antagonist, ozarelix, in benign prostatic hyperplasia.

Women With Breast Cancer Can Benefit From Prostate Drug – UK ...  -  May 19, 2007
Best Syndication,The drug, known as Luteinizing hormone-releasing hormone (LHRH), has been shown to be as effective as chemotherapy, but without the negative side effects.

AEterna Zentaris Regains Exclusive Worldwide (ex-Japan) Rights ...  -  May 9, 2007
PipelineReview.com (press release),AEterna Zentaris has regained exclusive worldwide (ex-Japan) rights for its lead Luteinizing Hormone-Releasing Hormone (LHRH) antagonist, cetrorelix in all

Spectrum Announces Completion Of Target Enrollment In Ozarelix ...  -  May 2, 2007
PipelineReview.com (press release),Ozarelix is a fourth generation Luteinizing Hormone Releasing Hormone (LHRH) antagonist administered as an intramuscular injection.

AEterna Zentaris Reports First Patients Treated with Cetrorelix ...  -  Apr 19, 2007
CNW Telbec (Communiqués de presse),...today reported dosing has commenced with its flagship product candidate, cetrorelix, the Company's lead luteinizing hormone-releasing hormone (LHRH)

Mixing Adjuvant Therapies Prolongs Early Breast Cancer Survival  -  Apr 4, 2007
Psychiatric Times,...induced by radiation, 22.8% had surgical ablation, and 8.4% took a luteinizing hormone-releasing hormone agonist every 28 days for at least two years.

Spectrum Pharmaceuticals Bolsters Ozarelix Team with Addition of ...  -  Apr 4, 2007
Drug Newswire (press release),Ozarelix is a fourth generation Luteinizing Hormone Releasing Hormone (LHRH) antagonist administered as an intramuscular injection.

AEterna Zentaris Reports Positive Results with Cetrorelix in BPH ...  -  Mar 29, 2007
Drug Newswire (press release),Results showed that cetrorelix, the Company's lead luteinizing hormone-releasing hormone (LHRH) antagonist, was safe and well tolerated at all dosage

Market Report -- In Play (AEZS)  -  Mar 22, 2007
MSN MoneyResults showed that cetrorelix, the co's lead luteinizing hormone-releasing hormone antagonist, was safe and well tolerated at all dosage regimens.

AEterna Zentaris Announce Positive Results With Cetrorelix In BPH ...  -  Mar 22, 2007
Trading Markets,According to the company, results showed that cetrorelix, the company's lead luteinizing hormone-releasing hormone antagonist, was safe and well tolerated

AEterna Zentaris Reports Positive Results For Phase 2a Trial ...  -  Mar 22, 2007
Trading Markets,The company initiated this Phase 2a trial with cetrorelix, which is the company's lead luteinizing hormone-releasing hormone (LHRH | charts | news

Spectrum Pharmaceuticals Bolsters Ozarelix Team With Addition Of ...  -  Mar 20, 2007
Medical News Today (press release),Ozarelix is a fourth generation Luteinizing Hormone Releasing Hormone (LHRH) antagonist administered as an intramuscular injection.

Spectrum Pharmaceuticals Bolsters Ozarelix Team with Addition of ...  -  Mar 19, 2007
PR Newswire (press release),About Ozarelix and Development Alliance with AEterna Zentaris Ozarelix is a fourth generation Luteinizing Hormone Releasing Hormone (LHRH) antagonist

MediGene's Six-Months Dosage of the Cancer Drug Eligard® Launched ...  -  Mar 1, 2007
PharmaLive.com (press release),About Eligard®: Eligard® is an LH-RH agonist (LH-RH = luteinizing hormone-releasing hormone) which significantly and consistently reduces the testosterone

Æterna Zentaris Initiates First Study of Phase 3 Program with ...  -  Jan 9, 2007
PipelineReview.com (press release),...in its Phase 3 program in benign prostatic hyperplasia (BPH) with its luteinizing hormone-releasing hormone (LHRH) antagonist compound, cetrorelix.

Spectrum Pharmaceuticals Announces FDA's Acceptance Of Ozarelix ...  -  Jan 5, 2007
Medical News Today (press release),Ozarelix is a fourth generation Luteinizing Hormone Releasing Hormone (LHRH) antagonist administered as an intramuscular injection.

Spectrum Pharmaceuticals Announces FDA's Acceptance of Ozarelix ...  -  Jan 3, 2007
PR Newswire (press release),About Ozarelix and Development Alliance with AEterna Zentaris Ozarelix is a fourth generation Luteinizing Hormone Releasing Hormone (LHRH) antagonist

AEterna Zentaris says tests results positive  -  Nov 27, 2006
Toronto Star,The trial includes 17 patients suffering from breast, endometrial and ovarian cancers with proven luteinizing hormone-releasing hormone receptor status.

MediGene's Drug Eligard Launched in Italy  -  Dec 18, 2006
PharmaLive.com (press release),About Eligard®: Eligard® is an LH-RH agonist (LH-RH = luteinizing hormone-releasing hormone) which significantly and consistently reduces the testosterone

Æterna Zentaris - Positive Top Line Phase 1 Results for AN-152 in ...  -  Nov 28, 2006
SpiritIndia,Human breast, endometrial and ovarian cancers commonly express receptors for luteinizing hormone-releasing hormone (LHRH-R). High-affinity binding sites for

AEterna Zentaris Reports Positive Top Line Phase 1 Results for AN ...  -  Nov 27, 2006
CNW Telbec (Communiqués de presse),Background Human breast, endometrial and ovarian cancers commonly express receptors for luteinizing hormone-releasing hormone (LHRH-R).

Æterna Zentaris to Initiate Phase 3 Program with Cetrorelix in BPH ...  -  Nov 30, 2006
PipelineReview.com (press release),3 program in benign prostatic hyperplasia (BPH) before year-end with its luteinizing hormone-releasing hormone (LHRH) antagonist compound, cetrorelix,

UPDATE 1-AEterna to start cetrorelix Phase 3 by year-end  -  Nov 29, 2006
ReutersTO: Quote, Profile, Research) said on Wednesday it plans to initiate before year-end a Phase 3 trial for cetrorelix, a luteinizing hormone-releasing hormone

Market Report -- In Play (AEZS)  -  Nov 29, 2006
MSN Money...its luteinizing hormone-releasing hormone antagonist compound, Cetrorelix, after the co's Investigational New Drug Application was accepted by the FDA.

Eligard(R) (leuprolide acetate) 6-Month Formulation Approved in ...  -  Dec 1, 2006
DG NewsEligard -- a palliative treatment for advanced prostate cancer, incorporates a luteinizing hormone-releasing hormone agonist, or LHRH agonist -- known as

Indevus Buyout of Valera to Grow Earnings  -  Dec 18, 2006
Seeking Alpha,Valera also sells Vantas, a 30 X 3.5 mm polymer cylinder that slowly leaches Histrelin acetate, a luteinizing hormone releasing hormone [LHRH],

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional